[Irinotecan and tomudex in the treatment of patients with advanced cancer of the large intestine].
The data on the treatment of 82 patients with advanced colorektal carcinoma are presented. Tomudex was given as first-line treatment to 18 cases. Apparent response was reported in 31% including complete (6%) and partial (25%) regression. Tumor growth control (apparent response + stabilization) was registered in 62%. Median survival rate was 38.4 weeks. Neutropenia, diarrhea and hepatotoxicity formation limited the modality. The treatment can be recommended for out-patients thanks to good tolerability and practical convenience. The following regimens of irinotecan were employed as first- and second-line chemotherapy (64): 250-350 mg/sq.m, every three weeks (44) and 100-125 mg/sq.m/week, x 4 every 6 weeks (20). Response was 15 and 16%, tumor growth control--60 and 63%, median survival--41.6 and 51.6% weeks, respectively. Leuko- and neutropenia and diarrhea development limited both regimens. Weekly infusions seemed to offer more advantage for out-patient treatment, particularly, in feeble patients and those who are a high risk for grave side-effects. Tomudex and irinotecan toxicity was predictable, moderate, reversible and non-cumulative.